Dividend26 May 2026, 12:56 pm
Marksans Pharma Recommends ₹0.90 Dividend for FY26
AI Summary
Marksans Pharma Ltd's board meeting on May 26, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹0.90 per equity share of face value ₹1 each (90%) for the financial year 2025-26, subject to member approval at the AGM. The dividend will be credited/dispatched within 30 days from the AGM date. MSKA & Associates LLP issued an unmodified opinion on the audited financial results.
Key Highlights
- Audited financial results for Q4 and FY26 approved with unmodified audit opinion.
- Final dividend of ₹0.90 per share (90%) recommended for FY26.
- Dividend payout is subject to shareholder approval at the AGM.
- Meeting commenced at 11:55 AM and concluded at 12:45 PM.
Price Impact
More from MARKSANS